MolecularMatch Releases Free COVID-19 and Coronavirus Trial Tracking Tool

HOUSTON, TX, April 14, 2020 – MolecularMatch, a leading clinical informatics company, has released a free, web-based portal to help researchers, physicians and patients find clinical trials for COVID-19 and coronavirus. The portal, available at, includes over 800 clinical trials across the globe for therapies and vaccines being tested for COVID-19. Physicians and patients can use their country, state or postal code to find enrolling trials nearest to the patient. Specific patient age, symptoms, severity and comorbidities are used to help find trials best suited to that individual. In addition to trials, the portal can also be used to search for literature and publications related to COVID-19.

“The number of therapeutic cures and vaccines being tested are growing at an astounding rate,” said Eric Pulaski, CEO at MolecularMatch. “Our tools make it easier for clinicians and patients to find the help they need. Hopefully, we can help save lives by shortening the time it takes to get more patients into clinical trials and by speeding up research to find cures and vaccines.”

MolecularMatch is providing the tool as a free public service in hopes of placing thousands of patients into trials as quickly as possible and saving researchers’ valuable time. Using the company’s highly-automated, AI-based curation platform, both the clinical trials database (currently, over 800) and publications (currently, over 2,400) are being updated every 2-3 days.

About MolecularMatch

MolecularMatch, Inc. is a Houston, Texas based clinical informatics SaaS company established in 2014. The company was founded on the vision of using tumor molecular profiling and outcomes from previously-treated patients to provide the best personalized treatment for current patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient. Customers include molecular labs, health information systems, biopharma, second opinion and payer companies, as well cancer centers on a global basis. Visit us at or follow us on Twitter or LinkedIn.